ES2088011T3 - Antagonistas de aminoacidos excitadores. - Google Patents

Antagonistas de aminoacidos excitadores.

Info

Publication number
ES2088011T3
ES2088011T3 ES91913891T ES91913891T ES2088011T3 ES 2088011 T3 ES2088011 T3 ES 2088011T3 ES 91913891 T ES91913891 T ES 91913891T ES 91913891 T ES91913891 T ES 91913891T ES 2088011 T3 ES2088011 T3 ES 2088011T3
Authority
ES
Spain
Prior art keywords
amino acid
acid antagonists
exciting amino
exciting
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913891T
Other languages
English (en)
Spanish (es)
Inventor
Francesco G Salituro
Bruce M Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2088011T3 publication Critical patent/ES2088011T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES91913891T 1990-07-16 1991-06-17 Antagonistas de aminoacidos excitadores. Expired - Lifetime ES2088011T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55605790A 1990-07-16 1990-07-16

Publications (1)

Publication Number Publication Date
ES2088011T3 true ES2088011T3 (es) 1996-08-01

Family

ID=24219725

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913891T Expired - Lifetime ES2088011T3 (es) 1990-07-16 1991-06-17 Antagonistas de aminoacidos excitadores.

Country Status (15)

Country Link
US (1) US5106847A (enExample)
EP (1) EP0539503B1 (enExample)
JP (1) JP3058688B2 (enExample)
KR (1) KR0178469B1 (enExample)
AT (1) ATE136295T1 (enExample)
AU (1) AU646686B2 (enExample)
CA (1) CA2087091C (enExample)
DE (1) DE69118539T2 (enExample)
DK (1) DK0539503T3 (enExample)
ES (1) ES2088011T3 (enExample)
FI (1) FI98455C (enExample)
GR (1) GR3019689T3 (enExample)
HU (1) HU216787B (enExample)
NO (1) NO179249C (enExample)
WO (1) WO1992001670A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5783575A (en) * 1994-03-14 1998-07-21 Novo Nordisk A/S Antagonists, their preparation and use
US5696148A (en) * 1994-03-14 1997-12-09 Novo Nordisk A/S Indole compounds and their use in treating diseases of the central nervous system
US5563157B1 (en) 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
EP0843660A1 (en) * 1995-07-31 1998-05-27 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
IL129187A0 (en) * 1996-09-30 2000-02-17 Hoechst Marion Roussel Inc NMDA (N-methyl-D-aspartate) antagonists
US6214856B1 (en) 1997-03-14 2001-04-10 Smithkline Beecham Corporation Indolecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
JP3334087B2 (ja) * 1990-09-10 2002-10-15 アヴェンティス ファーマシューティカルズ インコーポレイテッド 選択的ロイコトリエンｂ▲４▼拮抗剤活性を示す置換された二環式アリール化合物
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase

Also Published As

Publication number Publication date
FI930150L (fi) 1993-01-14
FI98455B (fi) 1997-03-14
US5106847A (en) 1992-04-21
FI98455C (fi) 1997-06-25
FI930150A0 (fi) 1993-01-14
KR0178469B1 (ko) 1999-03-20
HU216787B (hu) 1999-08-30
CA2087091A1 (en) 1992-01-17
JPH05508857A (ja) 1993-12-09
JP3058688B2 (ja) 2000-07-04
NO179249C (no) 1996-09-04
AU8290891A (en) 1992-02-18
NO930035D0 (no) 1993-01-07
EP0539503A1 (en) 1993-05-05
CA2087091C (en) 2001-09-11
EP0539503B1 (en) 1996-04-03
ATE136295T1 (de) 1996-04-15
DK0539503T3 (da) 1996-05-13
DE69118539T2 (de) 1996-09-19
WO1992001670A1 (en) 1992-02-06
AU646686B2 (en) 1994-03-03
HU9300100D0 (en) 1993-04-28
HUT67237A (en) 1995-03-28
EP0539503A4 (enExample) 1994-03-23
NO930035L (no) 1993-01-07
NO179249B (no) 1996-05-28
GR3019689T3 (en) 1996-07-31
DE69118539D1 (de) 1996-05-09

Similar Documents

Publication Publication Date Title
ES2088011T3 (es) Antagonistas de aminoacidos excitadores.
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
TR199801041T2 (xx) Kanabinoid resept�r afinitesine sahip olan 3-pirazolkarboksamid t�revleri.
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
FR2733244B1 (fr) Systeme de stabilisants a base de derives de polyalkylpiperidine
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
TR200000782T2 (tr) Resorsinol türevleri.
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
BG106947A (en) Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
MX9304581A (es) Desoxitaxoles y composiciones farmaceuticas que los contienen
MX168918B (es) Proceso para preparar compuestos de quinolona
PT929319E (pt) Ligandos transportadores de dopamina e serotonina e agentes de imagem
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
ES2078257T3 (es) Antagonistas de aminoacidos excitantes.
GT200200216A (es) Derivados del 3-azabiciclo [3.1.0] hexano
ATE229340T1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
DE69127755D1 (de) Okulare hypotensive 2-dekarboxyl-2-aminoalkyl-prostaglandine
MXPA94001345A (es) Derivados de poliamina como agentes radioprotectores.
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
MX9204866A (es) Arilpoliaminas sinteticas como antagonistas de neurotransmisores de aminoacidos excitadores.
ATE365036T1 (de) Creatinester-pronutrient-verbindungen und formulierungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539503

Country of ref document: ES